The complex role of interleukin-10 in autoimmunity

被引:156
作者
Groux, H [1 ]
Cottrez, F [1 ]
机构
[1] Hop Archet, INSERM U343, F-06200 Nice, France
关键词
interleukin-10; regulatory T-cells; tolerance; autoimmune diseases;
D O I
10.1016/S0896-8411(03)00044-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Interleukin- 10 (IL-10) is a cytokine that has been tested in different clinical trials based on its ability to down regulate T helper 1-type responses, namely IFN-gamma secretion and activation of monocytes/macrophages. There is also evidence in different animal models, that IL-10 could be useful in controlling Th2-mediated inflammatory processes. However, IL-10 also displays immunostimulatory properties especially on B cells and activated CD8(+) T cells. These seemingly divergent effects may explain the apparent lack of activity or adverse effects observed after IL-10 treatment in several animal models or clinical trials. Nevertheless, the ability of IL-10 to induce the differentiation of a subset of regulatory CD4(+) T cells (Tr1) and the importance of IL-10 for the in vivo function of regulatory T cells tends to support the view of IL-10 as a crucial cytokine in the control of immune responses. In different in vivo models, these cells were shown to inhibit Th1 and Th2-type inflammatory responses through the secretion of IL-10. These Tr1 cells may thus be used in specific cellular therapy in order to deliver IL-10 precisely at the site of inflammation. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:281 / 285
页数:5
相关论文
共 63 条
[1]
Origin of regulatory T cells with known specificity for antigen [J].
Apostolou, I ;
Sarukhan, A ;
Klein, L ;
von Boehmer, H .
NATURE IMMUNOLOGY, 2002, 3 (08) :756-763
[2]
ARAI T, 1995, J IMMUNOL, V155, P5743
[3]
Balasa B, 1998, J IMMUNOL, V161, P4420
[4]
In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines [J].
Barrat, FJ ;
Cua, DJ ;
Boonstra, A ;
Richards, DF ;
Crain, C ;
Savelkoul, HF ;
de Waal-Malefyt, R ;
Coffman, RL ;
Hawrylowicz, CM ;
O'Garra, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (05) :603-616
[5]
BENJAMIN D, 1992, BLOOD, V80, P1289
[6]
Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats [J].
Bethea, JR ;
Nagashima, H ;
Acosta, MC ;
Briceno, C ;
Gomez, F ;
Marcillo, AE ;
Loor, K ;
Green, J ;
Dietrich, WD .
JOURNAL OF NEUROTRAUMA, 1999, 16 (10) :851-863
[7]
INTERLEUKIN-10 ADMINISTRATION DECREASES SURVIVAL IN MURINE RECIPIENTS OF MAJOR HISTOCOMPATIBILITY COMPLEX DISPARATE DONOR BONE-MARROW GRAFTS [J].
BLAZAR, BR ;
TAYLOR, PA ;
SMITH, S ;
VALLERA, DA .
BLOOD, 1995, 85 (03) :842-851
[8]
MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-RESTRICTED CD8(+) T-CELLS AND CLASS II-RESTRICTED CD4(+) T-CELLS, RESPECTIVELY, MEDIATE AND REGULATE CONTACT SENSITIVITY TO DINITROFLUOROBENZENE [J].
BOUR, H ;
PEYRON, E ;
GAUCHERAND, M ;
GARRIGUE, JL ;
DESVIGNES, C ;
KAISERLIAN, D ;
REVILLARD, JP ;
NICOLAS, JF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (11) :3006-3010
[9]
EPSTEIN-BARR-VIRUS TRANSFORMATION INDUCES LYMPHOCYTES-B TO PRODUCE HUMAN INTERLEUKIN-10 [J].
BURDIN, N ;
PERONNE, C ;
BANCHEREAU, J ;
ROUSSET, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :295-304
[10]
PRODUCTION OF IL-10 BY MELANOMA-CELLS - EXAMINATION OF ITS ROLE IN IMMUNOSUPPRESSION MEDIATED BY MELANOMA [J].
CHEN, QY ;
DANIEL, V ;
MAHER, DW ;
HERSEY, P .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) :755-760